DE69920696T2 - Arylphosphatderivate von d4t mit anti-hiv wirkung - Google Patents

Arylphosphatderivate von d4t mit anti-hiv wirkung Download PDF

Info

Publication number
DE69920696T2
DE69920696T2 DE69920696T DE69920696T DE69920696T2 DE 69920696 T2 DE69920696 T2 DE 69920696T2 DE 69920696 T DE69920696 T DE 69920696T DE 69920696 T DE69920696 T DE 69920696T DE 69920696 T2 DE69920696 T2 DE 69920696T2
Authority
DE
Germany
Prior art keywords
hiv
cells
compound
derivatives
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69920696T
Other languages
German (de)
English (en)
Other versions
DE69920696D1 (de
Inventor
M. Fatih UCKUN
Rakesh Vig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parker Hughes Cancer Center
Original Assignee
Parker Hughes Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Cancer Center filed Critical Parker Hughes Cancer Center
Publication of DE69920696D1 publication Critical patent/DE69920696D1/de
Application granted granted Critical
Publication of DE69920696T2 publication Critical patent/DE69920696T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69920696T 1998-06-29 1999-06-29 Arylphosphatderivate von d4t mit anti-hiv wirkung Expired - Fee Related DE69920696T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/107,716 US6030957A (en) 1998-06-29 1998-06-29 Aryl phosphate derivatives of d4T having anti-HIV activity
US107716 1998-06-30
PCT/US1999/014774 WO2000000501A1 (en) 1998-06-29 1999-06-29 ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ANTI-HIV ACTIVITY

Publications (2)

Publication Number Publication Date
DE69920696D1 DE69920696D1 (de) 2004-11-04
DE69920696T2 true DE69920696T2 (de) 2006-03-02

Family

ID=22318071

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920696T Expired - Fee Related DE69920696T2 (de) 1998-06-29 1999-06-29 Arylphosphatderivate von d4t mit anti-hiv wirkung

Country Status (14)

Country Link
US (7) US6030957A (enExample)
EP (1) EP1090018B1 (enExample)
JP (1) JP2002519355A (enExample)
KR (1) KR20010071673A (enExample)
CN (1) CN1314909A (enExample)
AT (1) ATE277940T1 (enExample)
AU (1) AU4846999A (enExample)
BR (1) BR9911685A (enExample)
CA (1) CA2336285A1 (enExample)
DE (1) DE69920696T2 (enExample)
HU (1) HUP0102527A3 (enExample)
IL (1) IL140388A0 (enExample)
NO (1) NO20006685L (enExample)
WO (1) WO2000000501A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030957A (en) * 1998-06-29 2000-02-29 Wayne Hughes Institute Aryl phosphate derivatives of d4T having anti-HIV activity
US7144874B2 (en) * 2002-10-25 2006-12-05 Parker Hughes Institute Aryl phosphate derivatives of d4T having activity against resistant HIV strains
US20070015733A1 (en) * 1998-06-29 2007-01-18 Parker Hughes Institute Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains
WO2000056750A1 (en) * 1999-03-19 2000-09-28 Parker Hughes Institute One pot synthesis of 5'-hydroxy phosphorylated nucleoside derivatives, and compounds formed thereby
US6825177B2 (en) * 2000-10-30 2004-11-30 Parker Hughes Institute Aryl phosphate derivatives of d4T with potent anti-viral activity
PT1334108E (pt) * 2000-11-13 2005-08-31 Parker Hughes Inst Derivados arilfosfato da d4t
EP1513865A4 (en) * 2002-05-28 2006-05-03 Univ Minnesota USE OF CRISP POLYPPETIDES AS SPEECH CAPACITATION CONTACEPTIVES AND INHIBITORS
US20030236218A1 (en) * 2002-06-12 2003-12-25 Uckun Fatih M. Aryl phosphate derivatives of d4T with selective activity against adenovirus and HIV
US20040076931A1 (en) * 2002-10-18 2004-04-22 Cashflow Technologies, Inc. Educational interactive games
US20040077607A1 (en) * 2002-10-21 2004-04-22 Uckun Fatih M. Aryl phosphate derivatives of d4T with potent anti-viral activity against hemorrhagic fever viruses
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
US20070265222A1 (en) * 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
WO2006026656A1 (en) * 2004-08-31 2006-03-09 Parker Hughes Institute Cytotoxic nucleoside analog compound 003 for treating cancer
EP1827460A4 (en) * 2004-12-09 2012-03-14 Univ Minnesota NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
KR20080003789A (ko) * 2005-03-09 2008-01-08 더 리전츠 오브 더 유니버시티 오브 캘리포니아 나노복합체막 및 이의 제조 및 사용 방법
US7892618B2 (en) * 2005-03-21 2011-02-22 Sony Corporation Deterring theft of optical media
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
WO2010108140A1 (en) * 2009-03-20 2010-09-23 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707362A (en) 1985-02-15 1987-11-17 Biotek, Inc. Sustained release composition
US4841039A (en) 1986-05-01 1989-06-20 Emory University 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
JPH06189998A (ja) 1992-11-06 1994-07-12 C & Co:Yugen コンド―ム
WO1994014831A1 (en) 1992-12-18 1994-07-07 The University Of Alberta Dihydropyrimidine nucleosides with antiviral properties
ZA947572B (en) 1993-09-29 1995-09-28 Hampton Roads Medical College Contraceptive compositions
US5672698A (en) * 1993-11-15 1997-09-30 Bristol-Myers Squibb Co. Preparation of 2',3'-didehydro-3'-deoxythymidine from 5-methyluridine
US5659023A (en) * 1995-02-01 1997-08-19 Gilead Sciences, Inc. Nucleotide analogues
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
AU723081B2 (en) 1996-05-09 2000-08-17 Infectio Recherche Inc. Formulation for use in the prevention of pathogen induced diseases including HIV and HSV
US6030957A (en) * 1998-06-29 2000-02-29 Wayne Hughes Institute Aryl phosphate derivatives of d4T having anti-HIV activity

Also Published As

Publication number Publication date
WO2000000501A1 (en) 2000-01-06
HUP0102527A3 (en) 2002-04-29
DE69920696D1 (de) 2004-11-04
CA2336285A1 (en) 2000-01-06
US7071176B2 (en) 2006-07-04
ATE277940T1 (de) 2004-10-15
CN1314909A (zh) 2001-09-26
IL140388A0 (en) 2002-02-10
NO20006685L (no) 2001-02-28
NO20006685D0 (no) 2000-12-28
KR20010071673A (ko) 2001-07-31
JP2002519355A (ja) 2002-07-02
BR9911685A (pt) 2001-12-18
US6503890B1 (en) 2003-01-07
US6030957A (en) 2000-02-29
US6350736B1 (en) 2002-02-26
US6537975B1 (en) 2003-03-25
US6528495B1 (en) 2003-03-04
US6670336B1 (en) 2003-12-30
AU4846999A (en) 2000-01-17
HUP0102527A2 (hu) 2001-12-28
US20040171577A1 (en) 2004-09-02
EP1090018B1 (en) 2004-09-29
EP1090018A1 (en) 2001-04-11

Similar Documents

Publication Publication Date Title
EP0254268B1 (de) Fluorierte Nucleoside, ihre Herstellung und ihre pharmazeutische Verwendung gegen AIDS
DE3650130T2 (de) Antivirale Nukleoside.
EP1090018B1 (en) ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ANTI-HIV ACTIVITY
DE3852531T2 (de) Nukleoside und nukleosid-analoge, pharmazeutische zusammensetzung und verfahren für die herstellung der bestandteile.
DE69806919T2 (de) Antivirale pyrimidin-nukleosid-analogen
DE602005005240T2 (de) 4'-C-substituierte 2-Haloadenosinderivate
DE69634747T2 (de) Aryl-Ester Phosphoramidatderivate von 2',3'-Didehydronukleoside
DE69822482T2 (de) Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
DE69014562T2 (de) Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
WO1993016091A1 (de) Neue liponucleotide, deren herstellung sowie deren verwendung als antivirale arzneimittel
EP2137203B1 (de) Ethinylierte heterodinucleosidphosphatanaloga, verfahren zu deren herstellung und deren verwendung
WO1993016092A1 (de) Neue lipidphosphonsäure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel
EP0409227A2 (de) Pyrimidinnucleoside, ihre Herstellung und pharmazeutische Mittel
DE69031340T2 (de) 3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
EP0817790B1 (de) Spezifische lipidkonjugate von nucleosid-diphosphaten und deren verwendung als arzneimittel
EP0374096A1 (de) 2',3'-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür
DE69717568T2 (de) S-(+)-Adenosylmethionine und 3'-Azido-2',3'-Dideoxy-Nukleosid-Komplexe als potente Inhibitoren von HIV-Replikation
DE68927055T2 (de) 2',5'-oligoadenylat-derivate zur verwendung als heilmittel
DE19855963A1 (de) Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69332304T2 (de) Antivirale 2',5'-oligoadenylatderivate mit doppelter wirkung und ihre verwendungen
WO2009129798A2 (de) Di- und triphosphat-prodrugs, insbesondere nukleosiddi- und -triphosphat-prodrugs
DE60315164T2 (de) Partielle und volle agonisten von a1-adenosinrezeptoren
DE60020891T2 (de) Arylphosphatderivate von d4t
DD290808A5 (de) Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von durch retroviren verursachte infektionen bei mensch und tier
DD243502A1 (de) Verfahren zur herstellung von 5,6-disubstituierten uracilnucleosiden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee